Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT01797055
PHASE2

Apotransferrin in Atransferrinemia

Sponsor: Prothya Biosolutions

View on ClinicalTrials.gov

Summary

Atransferrinemia is a very rare disorder, which is caused by a deficiency of the protein transferrin. No regular treatment is available for these patients. The objective of this study is to investigate the pharmacokinetics, efficacy and safety of Apotransferrin replacement therapy in atransferrinemia patients.

Official title: Dose Escalating Study to Evaluate Pharmacokinetics, Efficacy and Safety of Apotransferrin in Atransferrinemia Patients

Key Details

Gender

All

Age Range

Any - Any

Study Type

INTERVENTIONAL

Enrollment

5

Start Date

2010-12

Completion Date

2028-01

Last Updated

2025-08-03

Healthy Volunteers

No

Interventions

DRUG

Human apotransferrin

intravenous infusion

Locations (3)

Klinikum Aschaffenburg

Aschaffenburg, Germany

AO San Gerardo

Monza, Italy

Vall d'Hebron Hospital

Barcelona, Spain